+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are conducting a prospective observational study to evaluate the diagnostic performance of PROSTest in men referred for prostate biopsy due to elevated PSA levels andor abnormal digital rectal examination. This study focuses on men aged 45 to 80 years and aims to compare PROSTest results with biopsy histopathology, the current standard for prostate cancer diagnosis. Participants will provide a peripheral blood sample before undergoing prostate biopsy. PROSTest analysis will be performed on these blood samples without knowledge of the biopsy results to ensure unbiased evaluation. The study will calculate diagnostic accuracy measures such as sensitivity, specificity, negative predictive value, and the area under the receiver operating characteristic curve. Additionally, the study will explore how PROSTest scores relate to MRI findings and pathologic grade groups. During the study, men will undergo blood collection and prostate biopsy as part of their clinical care. Researchers will analyze PROSTest diagnostic accuracy and secondary metrics after study completion, expected within 18 months. The study plans to enroll about 1,500 participants and monitor outcomes to assess PROSTests potential to reduce unnecessary biopsies and improve diagnostic decisions.

Age: 45Years - 80YearsMALE
1 location
S

Actively Recruiting

Researchers are studying whether tissue samples taken from the colon during routine colonoscopies can detect signs of Parkinsons disease or REM Sleep Behavior Disorder RBD. The study focuses on finding a protein called phosphorylated alpha-synuclein in colon tissue, which may help diagnose these conditions earlier than current methods that rely on symptoms. Early detection could allow doctors to begin treatment sooner when the disease is less advanced. During the routine colonoscopy procedure, doctors will take four small additional tissue samples from the colon two from each side. This adds only about two minutes to the standard procedure. After the colonoscopy, no extra visits are needed. The collected tissue samples will be tested for the alpha-synuclein protein to evaluate its presence in participants with Parkinsons disease or RBD. Participants will undergo the usual colonoscopy as planned, with the extra tissue sampling included. No individual test results will be given to participants. Researchers will measure the presence of phosphorylated alpha-synuclein in the colon tissue at the time of the procedure. The study involves 40 adults aged 40 to 99 who have Parkinsons disease or RBD and who are already scheduled for routine colonoscopy. The study is sponsored by CND Life Sciences and aims to improve early diagnosis of these neurological conditions.

Age: 40Years - 99YearsAll Genders
1 location
E

Actively Recruiting

Healthy Volunteer

This research aims to evaluate the Shield blood tests performance for colorectal cancer CRC screening in people aged 45 to 81 who are at average risk for CRC. The study focuses on assessing the test during a second round of screening, using colonoscopy as the reference standard. CRC is a common and serious disease, especially affecting older adults and certain minority groups, with early detection being key to improving outcomes. Participants will undergo the Shield blood test as part of their routine standard care, and their results will be compared to colonoscopy findings. This study is observational and collects real-world evidence over a period of 33 to 42 months after enrollment to assess how well the Shield test performs in detecting CRC or its precursors during the second screening interval. Participants will be involved in scheduled study procedures and standard care assessments, with data collected on the tests accuracy and effectiveness over time. The main outcome measured is the performance of the Shield test during the second testing period. The study will continue until December 2030, monitoring participants to gather long-term information about CRC screening efficacy in an average-risk population.

Age: 45Years - 81YearsAll Genders
69 locations